AbbVie Inc. (BCBA:ABBV)

Market Cap	474.12T
Revenue (ttm)	69.51T
Net Income (ttm)	4.44T
Shares Out	n/a
EPS (ttm)	2,502.76
PE Ratio	106.86
Forward PE	15.71
Dividend	534.09 (1.99%)
Ex-Dividend Date	Jul 15, 2025

Volume	686
Average Volume	1,213
Open	26,725
Previous Close	26,625
Day's Range	26,600 - 26,950
52-Week Range	18,325 - 27,925
Beta	n/a
RSI	70.40
Earnings Date	Jul 25, 2025

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2012
• Employees: 55,000
• Stock Exchange: Buenos Aires Stock Exchange
• Ticker Symbol: ABBV

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD